首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   61篇
  免费   1篇
儿科学   3篇
妇产科学   12篇
基础医学   3篇
口腔科学   14篇
临床医学   2篇
内科学   8篇
特种医学   1篇
外科学   6篇
综合类   2篇
预防医学   9篇
药学   1篇
肿瘤学   1篇
  2023年   2篇
  2022年   1篇
  2021年   4篇
  2020年   2篇
  2019年   4篇
  2017年   4篇
  2016年   1篇
  2015年   1篇
  2014年   2篇
  2013年   6篇
  2012年   4篇
  2011年   10篇
  2010年   2篇
  2009年   3篇
  2007年   2篇
  2006年   3篇
  2003年   2篇
  2002年   1篇
  2001年   1篇
  2000年   3篇
  1999年   1篇
  1996年   1篇
  1987年   1篇
  1933年   1篇
排序方式: 共有62条查询结果,搜索用时 828 毫秒
1.
2.
3.
INTRODUCTION: Although acute hepatitis E virus (HEV) infection is known to induce IgM and IgG humoral host immune responses, little is known about occurrence of cellular responses in this infection. We looked for evidence of lymphocyte sensitization to HEV peptides in patients with acute HEV infection. METHODS: peripheral blood lymphocytes were obtained from patients with acute hepatitis E and healthy controls. Proliferation of these lymphocytes in the presence of each of seven peptides with amino acid sequences corresponding to open reading frames 2 and 3 proteins of HEV (3 and 4 peptides, respectively) were studied; no peptide was added to control wells. Proliferative responses with stimulation indices exceeding 3.0 were taken as positive. RESULTS: More patients showed reactivity to two or more HEV peptides than did controls (11/21 vs 5/22, p<0.05). Reactivity to one peptide corresponding to open reading frame 2 of HEV was more frequent in patients than in controls (7/21 vs 1/22, p<0.05). CONCLUSION: Our results show that lymphocytes of patients with acute hepatitis E show sensitization to HEV peptides. This may have significance in understanding the pathogenetic mechanisms of liver injury in this infection.  相似文献   
4.
5.
6.
7.
8.
Transanal Endoscopic Microsurgical Resection of pT1 Rectal Tumors   总被引:7,自引:1,他引:6  
Purpose Transanal endoscopic microsurgery has emerged as an improved method of transanal excision of neoplasms because its enhanced visibility, superior optics, and longer reach permit a more complete excision and precise closure. This study will show that transanal endoscopic microsurgical treatment of pT1 rectal cancers is safe and achieves low local recurrence and high survival rates. Methods Retrospective review performed of all pT1 rectal cancers treated by a single surgeon (TS) using transanal endoscopic microsurgery between 1991 and 2003. Patient age, gender, tumor distance from the anal verge, lesion size, operative time, blood loss, complications, recurrence, and survival rates were prospectively recorded. Results Fifty-three patients (average age, 65.6 (range, 31–89) years) were studied. Forty-nine percent were male. Average tumor distance from the anal verge was 7 (range, 0–13) cm; average size was 2.4 (range, 1–10) cm. Radiation and/or chemotherapy were not administered. Sixteen patients had pT1 lesions removed piecemeal during colonoscopy; there was no residual tumor after transanal endoscopic microsurgical resection of the polyp site. Mean follow-up was 2.84 years. Fifty-one percent had longer than two-year follow-up. For the entire group, there were four recurrences (7.5 percent) occurring at 9 months, 15 months, 16 months, and 11 years. Two were treated with abdominoperineal resection, one with low anterior resection, and one with fulguration alone. There were no recurrences in the 16 patients who had excision of the polypectomy site. If excluded, recurrence was 11 percent (4/37). Patients were examined at three-month intervals for the first two years and every six months thereafter. There have been no cancer-related deaths. Conclusions Transanal endoscopic microsurgical resection of pT1 rectal cancers yields low recurrence rates. Close follow-up permits curative salvage for those that do recur. Transanal excision remains a viable option. Read at the meeting of The American Society of Colon and Rectal Surgeons, Dallas, Texas, May 8 to 13, 2004. Reprints are not available.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号